Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease

BACKGROUND: TreXTAM(® )is a combination of the key regulatory cytokine transforming growth factor beta (TGFβ) and all trans retinoic acid (ATRA) microencapsulated for oral delivery to immune structures of the gut. It is in development as a novel treatment for inflammatory bowel disease (IBD). AIM: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammer, Laura, Furtado, Stacia, Mathiowitz, Edith, Auci, Dominick L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667406/
https://www.ncbi.nlm.nih.gov/pubmed/33251033
http://dx.doi.org/10.4292/wjgpt.v11.i5.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667406/
https://www.ncbi.nlm.nih.gov/pubmed/33251033
http://dx.doi.org/10.4292/wjgpt.v11.i5.79

Ejemplares similares